We use cookies to ensure that the website works as intended and to collect statistics on its use so that we can improve your web site experience.


Aker BioMarine - second quarter 2022

Back to news

14 July 2022: Aker BioMarine ASA (“Aker BioMarine” or “the company”) reports revenues of USD 73 million and Adjusted EBITDA of USD 21 million for the second quarter 2022.

Aker BioMarine Q2 2022 Report

Aker BioMarine Q1 2022 Slide deck

“Aker BioMarine delivers good profitability in the quarter, specially driven by high sales volumes and prices for Qrill Aqua. The company has also improved krill harvesting, and so far this year Antarctic production of krill meal is 39,000 tons, 13% above last year. The Superba krill oil sales organization is strengthened in all geographies and will execute on the upgraded pipeline to deliver growth. We reiterate our financial targets for the full year 2022”, said Matts Johansen, CEO of Aker BioMarine.

Highlights second quarter:

  • Revenues of USD 73 million, on par with the same quarter last year
  • Adjusted EBITDA of USD 21 million, up 11% from the same quarter last year
  • Net profit of USD 15 million, up from USD -3 million the same quarter last year
  • Sales in the Ingredients segment, up 8% from same quarter last year
  • Sales in the Brands segment, down 16% from same quarter last year
  • Offshore production volume at 16,500 tons, the highest second quarter ever and up 19% from same quarter last year

Aker BioMarine reiterates its targets for 2022 with a sales growth of between 20-25%, and an Adjusted EBITDA margin of 20-25%.

At 09:00 CET today, the management hosts a webcast. Following the presentation, there will be a Q&A session, where written questions can be submitted to ir@akerbiomarine.com.

The webcasted presentation will be in English. To join, please use the link that is available at www.akerbiomarine.com/investor.

A replay of the presentation and Q&A session material will be made available soon after the presentation at the same web address.

For further information, please contact
Carl Christian Bachke, Investor Relations
Mobile: +47 909 808 48
Email: carl.bachke@akerbiomarine.com

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.

About Aker BioMarine

Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting company developing krill-derived products for pharma, consumer health and wellness as well as animal nutrition. The company has a strong position in its industry and is the world's leading supplier of krill, the natural, powerful and health promoting source of nutrients from the pristine waters of Antarctica. Aker BioMarine is listed on Oslo Stock Exchange (AKBM). More information is available at www.akerbiomarine.com.